Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Malini Khanna

Interventional Pain Medicine Sewell, NJ Medical Doctor

NPI 1306087200 CMS profile 285950

570 Egg Harbor Rd, Suite C4, Sewell, NJ 08080

Open in the dashboard

General payments

$6,336

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Malini Khanna of Sewell, NJ is reported in the CMS Open Payments database as having received $6,336 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,394 15
2024 General $1,548 25
2023 General $504 11
2019 General $1,890 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Malini Khanna
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Malini Khanna were reported at $2,394. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Malini Khanna Interventional Pain Medicine median Middle half National median
2019 $1,890 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $504 $671 $195–$1,915 $160
2024 $1,548 $684 $206–$1,837 $164
2025 $2,394 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $2,258 8 payments
  2. Liberty Surgical, Inc $1,877 1 payment
  3. Eclipse Technology Solutions Inc. $752 2 payments
  4. SI-BONE, Inc. $393 7 payments
  5. DePuy Synthes Sales Inc. $384 24 payments
  6. AbbVie, Inc. $301 3 payments
  7. Arthrex, Inc. $283 3 payments
  8. Avanos Medical $35 2 payments
  9. Ossur Americas., Inc $24 1 payment
  10. Stryker Corporation $16 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,916 7 payments
  2. Education $1,877 1 payment
  3. Food and Beverage $1,543 45 payments
Products named General payments · program years 2019–2025
  1. Iovera $2,258 8 payments
  2. ORTHOVISC $384 24 payments
  3. MONOVISC $358 23 payments
  4. PEAK $358 23 payments
  5. GENERATOR $35 2 payments
  6. Unloader One X $24 1 payment
  7. SPINEJACK $16 1 payment
  8. SonicOne $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

211

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$1,044

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

14.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 70 $385
Celecoxib Generic 37 $281
Methylprednisolone Generic 27 $128
Tizanidine Hcl Generic 21 $87
Tramadol Hcl Generic 26 $65
Acetaminophen-Codeine Acetaminophen With Codeine Brand 15 $60
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$164,941

Of which drugs: $12,787

Medicare patients

155

Average age 75

Services billed

2,633

102 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 26%
Diabetes 25%
Depression 25%
Osteoporosis 23%
Cancer 18%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 16 91 $9,014
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 37 191 $144
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 58 443 $40
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 43 123 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record